-
NBA fines 76ers' Drummond, Magic's Suggs $25,000 each
-
Switzerland's Ehammer sets indoor heptathlon world record
-
Pogacar 'relieved' by Milan-San Remo triumph, gunning to complete Monument set
-
World Athletics decision to hand Asia two world indoors 'strategic' - Coe
-
Trump threatens to use ICE agents for airport security control
-
Kane moves closer to goals record as Bayern sink Union
-
Pogacar ends long wait for Milan-San Remo glory after edging epic
-
US says 'took out' Iran base threatening blocked Hormuz oil route
-
Di Giannantonio takes Brazil MotoGP pole ahead of Bezzecchi, Marquez
-
Welbeck scores twice to dent Liverpool's top-five hopes
-
US strikes Iran bases threatening blocked Hormuz oil route
-
Pirovano wins World Cup downhill title, Aicher puts pressure on Shiffrin
-
Doroshchuk wins Ukraine's second world indoor gold, Hodgkinson and Alfred coast
-
K-pop kings BTS stun Seoul in '2.0' comeback concert
-
French prosecutors suspect Musk encouraged deepfakes row to inflate X value
-
Mbappe 100 percent, Bellingham fit, says Real Madrid's Arbeloa
-
Iranians mark Eid as Tehran reports strike on nuclear plant
-
Kenya, Uganda open rail extension burdened by Chinese debt
-
K-pop kings BTS rock Seoul in comeback concert
-
Invincible Japan edge Australia to win Women's Asian Cup
-
Italy's Paris claims first win of season in World Cup downhill finale
-
In Finland, divers learn to explore icy polar waters
-
Dortmund extend injured captain Can's contract
-
Iranians mark Eid as Trump mulls winding down war
-
Matisse's last years cut out -- but not pasted -- at Paris expo
-
BTS fans take over central Seoul for K-pop kings' comeback
-
Star jockey McDonald becomes horse racing's most prolific Group 1 winner
-
Israel strikes Tehran, Beirut as Trump mulls 'winding down' war
-
Pistons top Warriors to clinch NBA playoff berth
-
Tickets to toothbrushes: BTS's money-making machine
-
Top-ranked Alcaraz, Sabalenka win Miami openers
-
After Cuba beckons, Miami entrepreneurs are mostly reluctant to invest in the island
-
Peru's crowded presidential race zeroes in on organized crime
-
Taiwan's Lin to compete in first international event since Paris gender row
-
BTS takes over central Seoul for comeback concert
-
Jury signals tech titans on hook for social media addiction
-
Brumbies mark Slipper record in thriller against Chiefs
-
US jury finds Elon Musk misled Twitter shareholders
-
Gauff rallies to avance at Miami Open
-
WNBA, players union confirm agreement on 'groundbreaking' labor deal
-
Carrick 'baffled' by inconsistent penalty calls as Man Utd held
-
Trump says considering 'winding down' Iran war but rules out ceasefire
-
Trump mulls 'winding down' Iran war
-
Man Utd held by Bournemouth after Maguire sees red
-
Lens go top of Ligue 1 with handsome Angers win
-
Leipzig pummel Hoffenheim to climb to third
-
Quinn ousts 11th seed Ruud at rain-hit Miami Open
-
Rap group Kneecap says crisis-hit Cuba being 'strangled'
-
Anthony, Jackson nail US double at world indoors
-
Zarco seizes his moment as rain disrupts Brazil MotoGP practice
US FDA says Pfizer Covid vaccine effective in kids under five
The US Food and Drug Administration (FDA) has said the Pfizer Covid vaccine is safe and effective in children under five, ahead of a meeting to weigh its authorization later this week.
Children under five are the only age group not yet eligible for vaccination in the United States and most countries, a pressing need since rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age," the FDA said in a document posted on its website Sunday.
The agency has called a meeting of experts on June 15 to decide whether to recommend the Pfizer vaccine, given as three shots to children aged six months through four years, as well as the Moderna vaccine, given as two shots to children aged six months through five years.
Pfizer's first two shots are given three weeks apart, then the third is given eight weeks after the second. They are all dosed at three micrograms, as opposed to 30 micrograms the company gives older ages.
Both Pfizer and Moderna had previously posted their results, but the FDA then had to review the data in detail and carry out its own evaluation. It posted a favorable analysis about Moderna on Friday.
Its comments towards Pfizer also appear favorable, based on the levels of infection-blocking antibodies it evoked in trial participants, and a similar side-effect profile to higher age groups. The trial population was around 4,500 children.
A preliminary estimate placed vaccine efficacy at 80.3 percent, but the FDA noted this was based on very few positive cases -- just 10, as opposed to the 21 sought for a more accurate figure.
There are nearly 20 million US children aged four years and under, or six percent of the population. If, as expected, the FDA-appointed experts recommend the two shots, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
P.L.Madureira--PC